Abbott India Launches Dual-Chamber Leadless Pacemaker System Revolutionising Cardiac Care

Mumbai, 7 October 2025: Abbott India Ltd (NSE: ABBOTINDIA), a leading global healthcare company, has launched its dual-chamber leadless pacemaker system in India, marking a significant advancement in cardiac rhythm management by enabling wireless synchronisation between two miniature pacemakers implanted directly inside the heart.

Dual-Chamber Leadless Pacemaker Introduces Next-Generation Cardiac Rhythm Technology

Pacemakers traditionally treat bradycardia, a condition where the heart beats too slowly, but conventional devices rely on wires and surgical pockets. Abbott’s AVEIR DR leadless pacemaker system overcomes these limitations by providing wireless communication and coordination between two miniature devices, each smaller than an AAA battery. The breakthrough allows real-time synchronisation between the right atrium and right ventricle, improving efficiency in regulating heart rhythm while reducing procedural risks.

AVEIR DR System Enables Precise Beat-by-Beat Synchronisation for Improved Heart Function

The AVEIR DR system consists of two devices: AVEIR VR, which regulates the right ventricle, and AVEIR AR, which controls the right atrium. By communicating in real time, the pacemakers ensure seamless coordination between the heart’s upper and lower chambers. Previously, leadless pacemakers could manage only a single chamber, but Abbott’s innovation allows dual-chamber management, overcoming a major technical hurdle in cardiac pacing technology.

Smaller, Safer Devices Reduce Invasiveness and Complication Risks

Each pacemaker in the AVEIR DR system is roughly one-tenth the size of a conventional pacemaker, making implantation less invasive. The wireless design eliminates risks associated with leads and surgical pockets, potentially reducing complications and improving patient recovery. Abbott emphasises that this system expands treatment options for patients who previously had limited leadless pacing solutions.

Share Price Responds Moderately Despite Breakthrough Launch

Following the announcement, Abbott India shares were trading at ₹29,950, down ₹70 (0.23%) as of 12:36 PM IST on 7 October 2025. The stock opened at ₹30,045, touched a high of ₹30,190, and a low of ₹29,940 during the session. Market capitalisation stood at ₹63,640 crore, with a P/E ratio of 43.82 and a quarterly dividend of ₹119.05. Despite the technological breakthrough, the moderate market response reflects broader market dynamics and sector-wide trading trends.

Abbott India’s launch of the dual-chamber leadless pacemaker highlights the growing shift toward minimally invasive, wireless cardiac solutions. The innovation demonstrates how device miniaturisation and real-time chamber synchronisation can improve patient outcomes, reduce procedural complications, and support the expansion of advanced cardiac care services in India.

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations